Myant Enhances Cardiovascular Precision Medicine with Acquisition of mmHg

Myant has announced its acquisition of mmHg Inc., a digital health company specializing in remote blood pressure monitoring and cardiovascular risk management. This strategic acquisition extends Myant’s reach into the U.S. market, where mmHg boasts a substantial customer base and a key partnership with A&D Medical, a top manufacturer of medical devices and health products. This move is a crucial part of Myant’s broader strategy to revolutionize personalized healthcare through AI-enabled, remote technologies.

Alberta, Canada-based mmHg is renowned for its platform that enables healthcare providers to efficiently manage cardiovascular health, particularly in remote settings. The platform allows for the continuous tracking and analysis of blood pressure and other critical cardiovascular indicators, aligning real-time patient data with clinical best practices to enhance decision-making and improve patient outcomes. Renowned institutions like Beth Israel Deaconess (Harvard Medical), Johns Hopkins, and Columbia University utilize mmHg’s technology to bolster both patient care and clinical research.

The integration of mmHg’s remote monitoring technology with Myant’s innovative textile computing capabilities will provide healthcare providers with uninterrupted access to real-time patient data. This synergy will facilitate earlier detection of health risks, tailor personalized treatment plans, and improve chronic condition management, ultimately enhancing patient health outcomes and quality of life. “This acquisition is a transformative step towards redefining healthy aging and chronic disease management, enabling an aging population to live healthier, longer lives,” said Tony Chahine, CEO of Myant. Peter Wood, COO at mmHg, added, “Our combined technologies will set a new standard in personalized healthcare, where continuous, clinical-grade vitals are seamlessly integrated into patient care.”